Key Clinical & Pre-clinical Resource Guide
Clinical

1. Study Title

NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial

Full list of Authors
Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK.

Full AMA Reference

Study Design
Level-I clinical study: prospective, multi-centre, randomized (1:1), corticosteroid-controlled, double-blind.

Objective
To compare, in a non-inferiority trial, the effectiveness and safety of a single intra-articular injection of NASHA® (DUROLANE®) with a commonly used steroid; Methylprednisone Acetate (MPA).

Results
442 patients with knee OA were randomly assigned to a treatment group (221 DUROLANE, 221 MPA). Results were similar between MPA and DUROLANE at 6-18 weeks (WOMAC pain responder rate). However, there was a significant reduction in the pain responders* from weeks 18-26 in the MPA group which was not observed in the DUROLANE group. In response to a second DUROLANE treatment at 26 weeks, sustained improvements were seen in WOMAC outcomes irrespective of initial treatment. No serious device-related AEs were reported.

*Pain responder rate: the percentage of patients with ≥40% improvement from baseline in WOMAC pain score and an absolute improvement of ≥5 points.

2. Study Title

A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis

Full list of Authors
Arden NK, Åkermark C, Andersson M, Todman MG, Altman RD.

Full AMA Reference

Study Design
Level-I clinical study: multi-centre, randomized, double-blind, saline-controlled.

Objective
A 6 week saline-controlled study to investigate the safety and efficacy of NASHA in patients with mild–moderate structural OA confined to the study knee.

Results
218 patients with KL grade II –III OA in a single knee were randomized into two treatment groups (DUROLANE 108, saline 110). No statistically significant difference in responder rate* was found between the two groups at 6 weeks (NASHA: 30.6%; saline: 26.4%). A post-hoc subgroup analysis of patients without clinical effusion in the study knee at baseline showed a significantly higher (p=0.0084) 6 week responder rate with NASHA (NASHA: 40.6%; saline: 19.7%).

*Pain responder rate: the percentage of patients with ≥40% improvement from baseline in WOMAC pain score and an absolute improvement of ≥5 points.
3. Study Title
A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis

Full list of Authors
McGrath AF, McGrath AM, Jessop ZM, Gandham S, Datta G, Dawson-Bowling S, Cannon SR.

Full AMA Reference

Objective
To compare the efficacy and complications of two single injection HA treatments for knee OA (Synvisc-One® and DUROLANE).

Results
182 knees were treated with KL-II and KL-III grade osteoarthritis. Patients were followed up at 3, 6, 9 and 12 months. Significant improvement were seen in the VAS, SF 36 V2 and Oxford Knee Scores (p=0.01). At 6 months, the difference from baseline values was significantly different in the DUROLANE group (p=0.0001), but not for the Synvisc® group (p=0.783). Adverse reactions occur significantly less with the more effective product. Nine (9) patients experienced an adverse event. Results suggest that HA treatment for mild to moderate OA can provide pain relief for up to six months along with reducing the need for analgesic and anti-inflammatory medication.

Click here to view abstract

4. Study Title
Factors related with the time to surgery in waiting-list patients for knee prostheses

Full list of Authors
Jurado MR, Fidalgo AE, Villar VR, Medina JM, Lopez BS.

Full AMA Reference

Study Design
Level-II clinical study: single centre, retrospective cohort study.

Objective
To assess if DUROLANE treatment could delay the need for a total knee replacement.

Results
Data was collected on 224 patients requiring TKR, 202 (90.2%) of these patients were treated with DUROLANE. KL grades varied from grade I to grade IV (9% KL-I, 27.5% KL-II, 48.2% KL-III, 15.3% KL-IV). In the stratified analysis, treatment with DUROLANE extended time until surgery in the group of patients with KL-III close to statistical significance (P=0.064). The median survival of patients with grade 3 lesions and DUROLANE treatment was 1278 days (95%, 474–2081) and for those not receiving treatment it was 596 days (95% CI, 14–1179).

Click here to view abstract
Safety, efficacy and predictive factors of efficacy of a single intra-articular injection of non-animal-stabilized-hyaluronic-acid in the hip joint: results of a standardized follow-up of patients treated for hip osteoarthritis in daily practice


Level-III clinical study: single centre, uncontrolled study.

To report on the efficacy and tolerability of a single intra-articular injection of NASHA in patients treated for symptomatic hip OA.

34 patients with primary hip OA ranging from KL grades I – IV were treated with DUROLANE. All clinical variables (Walking Pain, Patient Global Assessment, WOMAC, Lequesne index) decreased significantly between baseline and last evaluation at 180 days. The percentage of “responder” patients according to the OMERACT-OARSI criteria* (71% of the assessable patients, 55% of the total number of treated patients) suggested that the majority of patients derived benefit of the treatment.


Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid

Krocker D, Matziolis G, Tuischer J, Funk J, Tohtz S, Buttgereit F, Perka C.


Level-III clinical study: single centre, uncontrolled study.

To examine the efficacy of a single intra-articular injection of DUROLANE measured based on pain, functioning, and quality of life in patients with knee joint arthritis.

50 patients with KL grade I-III OA of the knee were treated with a single injection of DUROLANE. Patients were followed up at 2 and 24 weeks post injection. At all three visits, Range of Motion (ROM), Knee Osteoarthritis Outcome Score (KOOS), EuroQol 5D (EQ5D) and Visual Analogue Score (VAS) were recorded. Two weeks post injection there was a non-statistical improvement in quality of life, 24 weeks after the injection there was a significant improvement (p<0.01) in all parameters as compared to baseline values.
Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee


Level-I clinical study: multi centre, randomized, double blind and saline controlled. This study was performed to investigate the safety and efficacy of single-injection NASHA compared with placebo in patients with OA of the knee.

346 patients with knee OA were randomized to a treatment group (172 DUROLANE, 174 saline). WOMAC and SF-36 scores were recorded at baseline and follow up visits at weeks 2, 6, 13 and 26 post injection. For the overall population, there were no statistically significant between-group differences in response rates for any efficacy parameters. In patients with OA confined to the knee (N=216), a greater responder rate* to NASHA than placebo was observed at week 6 (P=0.025).

*Pain responder rate: the percentage of patients with ≥40% improvement from baseline in WOMAC pain score and an absolute improvement of ≥5 points.

Click here to view abstract

Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: A pilot study


Level-III clinical study: single centre, prospective open label, pilot study. To assess the safety and potential efficacy of intra-articular non-animal stabilised hyaluronic acid (NASHA) in patients with hip OA.

31 patients with KL II-III osteoarthritis in the hip were treated with DUROLANE. Follow up was made at 2 weeks and 3 months post injection. A positive response was defined as a > or = 40% reduction in the WOMAC pain score from baseline, together with an absolute decrease of > or = 5 points. The response rate was 50% at 2 weeks and 54% at 3 months. In the extension population the response rates were 69% at 3 months and 44% at 6 months. There were 9 treatment related adverse events, the majority of which were arthralgia. Adverse reactions were generally transient and all patients made a full recovery.

Click here to view abstract
Elimination of stabilised hyaluronan from the knee joint in healthy men


Level-III clinical study: single center, uncontrolled study.

To investigate the elimination of stabilised hyaluronan following intra-articular injection into the knee joint of healthy men.

6 male subjects were injected with 3ml of radiolabeled DUROLANE into the knee joint. Radioactivity levels were then measured to assess how long it took for the DUROLANE to be eliminated from the human knee joint. Elimination of DUROLANE from the joint was described by three distinct phases, with half-lives of 1.5 hours, 1.5 days and 4 weeks. Most likely, the last value reflects the true half-life of DUROLANE.

Non-animal stabilised hyaluronic acid in the treatment of osteoarthritis of the knee: A tolerability study

Åkermark C, Berg P, Bjorkman A, Malm P.


Level-III clinical study: multi-centre, non-blinded, prospective tolerability study with extension phase.

To evaluate the safety of an intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) in patients with osteoarthritis (OA) of the knee, with an extension phase to assess the safety of a second repeat injection.

103 patients (128 knees) with arthroscopically verified OA were treated with a single injection of DUROLANE. Patients were followed up 2 weeks and 3 months post injection. VAS was measured at each clinic visit and overall satisfaction was measured at the 3 month follow up. After the first injection 7 of the reported local reactions fulfilled the criteria to be classed as a device related adverse event (AE) (knee pain and swelling). 53 patients received a second injection (6.5-9.5 months after first injection), this was followed up 1 month later. After the second injection 11 events were considered potentially related to the study product or the injection procedure, of which three were classed as device-related, unanticipated adverse events, giving an event frequency of 4% in 72 injections. A statistically significant reduction in knee pain (p < 0.0001) was seen after both injections.
Non-animal stabilized hyaluronic acid: A new formulation for the treatment of osteoarthritis

Agerup B, Berg P, Akermark C.


Pre-clinical review article.

This article aims to describe the structures of HA products, how they are produced and summarises clinical findings. The two main HA treatments addressed in this review are Hylan G-F 20 and DUROLANE.

Agerup et al. clearly describe how Hylan G-F 20 is produced by combining Hylan A and Hylan B. Hylan is extracted from rooster combs following pretreatment with formaldehyde to produce crosslinks between amino acids and animal proteins. This crosslinking results in a protein content of 0.4 – 0.8% in Hylan A. Hylan B is produced by further crosslinking Hylan A with divinyl sulfone to produce a gel. The crosslinking in Hylan B is approximately 20%. They also discuss the half life of Hylan A being 1.5 days and 8.5 days for Hylan B and that Hylan G-F 20 has been associated with adverse events and complications such as swelling and pain in the treated joint, but also serious adverse events such as aseptic acute arthritis, synovitis, pseudogout and anaphylactic shock.

In comparison, Agerup et al. describe the production of DUROLANE using NASHA technology. This involves the secretion of HA from the cellular membrane of bacteria into media. The HA is then extracted from the media and crosslinked at the hydroxyl groups with 1, 4-butanediol diglycidyl ether, this crosslinking is limited to 0.5 – 1%. The true half life of DUROLANE is described as being 4 weeks. Regarding safety, the authors discuss that NASHA products have been used for cosmetic purposes without any safety concerns. Lastly, in a tolerability study as a viscosupplementation treatment only general transient reactions were experienced which required no treatment.
A study of the ability of Durolane to withstand degradation by free radicals while maintaining its viscoelastic properties

Pre-clinical investigation.

This preclinical investigation was carried out to determine how Synvisc® and DUROLANE are degraded by reactive oxygen species (ROS) compared to normal and osteoarthritic synovial fluid.

Results

Oxidative stress with increased concentrations of ROS result in HA degradation in inflammatory diseases of the joints. DUROLANE and Synvisc® were exposed to free radicals in both their normal and diluted state. Their viscoelastic property was measured over a 90 minute period using the storage (G’) and loss (G”) moduli. These were then compared to data of normal and arthritic human synovial fluids. DUROLANE showed the ability to retain its storage modulus, which represents the elasticity of the product, over the level of normal synovial fluid during the degradation. This was found for the undiluted as well as for the diluted sample. Immediately after the onset of degradation, both the storage and loss moduli of undiluted Synvisc® were in the same order of magnitude as normal synovial fluid but this dropped rapidly. The diluted Synvisc® showed properties closer to pathologic synovial fluid.

Intraarticular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis

Pre-clinical investigation using control groups and TGFβ1 and exercise induced osteoarthritis model in mice.

Objective

The objective of this study was to examine the effect of intraarticular HA injection on well-defined stages of the initiation and progression of murine OA. Using a TGFβ1 and exercise induced OA model in mice, investigators performed macroscopic and microscopic evaluations of joint tissue structure, determined mechanical allodynia (pain caused by stimuli that do not normally evoke pain) and locomotive function of the hindlimbs.

Results

Osteoarthritis was induced in mice by injecting TGFβ1 and running the mice uphill for 2 weeks. Animals were injected with either HA or saline the day before running commenced. A control group was run only. Gait analysis showed that OA development in this model was accompanied by significant (P < 0.01) enhancement of the stance and propulsion times of affected legs. HA injection (but not saline injection) blocked all
gait changes. Analysis of the joints also showed that HA protected joints from femoral cartilage erosion as well as tibial and femoral tissue fibrosis. Both HA injection and saline injection attenuated acute allodynia, but the HA effect was more pronounced and prolonged than the saline injection.

4. Study Title
Evaluation of the biocompatibility of Durolane using the murine air pouch model

Full list of Authors
Wooley PH, Song Z, Harrison A.

Full AMA Reference
Wooley PH, Song Z, Harrison A. Evaluation of the biocompatibility of Durolane using the murine air pouch model. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society; February 2009; Las Vegas, NV.

Study Design
Pre-clinical in-vivo study using an air pouch model in mice, an in-vitro testing to analyse inflammatory response.

Objective
This study investigated the antigenicity of DUROLANE in the murine air pouch biocompatibility evaluation, and examined the potential to generate an antibody reaction in mice exposed to viscosupplement using the air pouch model.

Results
Air pouches were created in the backs of 30 mice after 6 days these were then divided into 5 treatment groups and injected with 500ul saline, DUROLANE, Synvisc®, EUFLEXXA® or Positive control pouches were stimulated by the injection of 500ul of sterile saline UHMWPE particle suspension. After 14 days the tissue thickness of the pouch and antibody levels were measured by ELISA in order to evaluate if the injected products created an inflammatory response. Analysis of the air pouch tissue showed significant increase in thickness beyond that of the control for all HA products except DUROLANE, with Synvisc® creating the largest amount of tissue inflammation. The cause of the inflammation was shown to be in infiltration of both inflammatory cells and fibroblasts with the largest inflammatory cell infiltration being caused by Synvisc®. DUROLANE only stimulated fibroblast infiltration. Moderate increases in both TNFalpha and IL-6 in membrane extracted proteins supported the histological observations of modest inflammation and fibroblast proliferation. There was no significant antibody production created by the injection of DUROLANE or EUFLEXXA®, however, there were consistently elevated levels of antibodies created by the injection of Synvisc®.
Hyaluronic acid viscosupplements from avian and non-mammalian sources exhibit biocompatibility profiles with unique, source-specific, antigenic profiles.


**Study Design**
Pre-clinical in-vivo study using an air pouch model in mice.

**Objective**
The objective of this work was to compare two HA supplements from non-mammalian sources (LMWHA and NASHA) with a viscosupplement derived from an avian source (Hylan G-F 20) with respect to their biocompatibility within an inflammatory tissue model and their immunological profile.

**Conclusion**
Air pouches were created in the back of 30 mice. After 6 days these mice were divided into 5 treatment groups and injected with 500ul saline, DUROLANE, Synvisc®, low molecular weight HA, or Positive control. Pouches were stimulated by the injection of 500ul of sterile saline UHMWPE particle suspension. After 14 days the tissue thickness of the pouch and antibody levels were measured by ELISA in order to evaluate if the injected products created an inflammatory response. Analysis of the air pouch tissue showed significant increase in thickness beyond that of the control for all HA products except DUROLANE, with Synvisc® creating the largest amount of tissue inflammation. The cause of the inflammation was shown to be an infiltration of both inflammatory cells and fibroblasts with the largest inflammatory cell infiltration being caused by Synvisc®. DUROLANE only stimulated fibroblast infiltration. Moderate increases in both TNFalpha and IL-6 in membrane extracted proteins supported the histological observations of modest inflammation and fibroblast proliferation.

An additional 24 animals were immunized with HA products in complete freunds adjuvant, in order to stimulate the immune system, these animals were then treated with HA products. A high antibody response was seen in mice injected with HA from an avian source, while low reactivity was observed in sera from mice injected with HA from bacterial sources. There was no indication of a cross-reaction, suggesting that patients with adverse immune responses to HA from an avian source should be unresponsive to a subsequent injection with HA from a non-avian source.
Summary of Indications for Use
DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.
DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.
There are no known contraindications.
You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.
Risks can include transient pain, swelling and/or stiffness at the injection site.
Full prescribing information can be found in product labeling, or at www.durolane.com.